Phreesia (NYSE:PHR) General Counsel Allison Hoffman Sells 14,483 Shares

Key Points

• General Counsel Allison Hoffman sold 14,483 shares on April 10 at an average price of $8.07 under a Rule 10b5-1 plan to cover tax withholding, reducing her stake by 8.14% to 163,485 shares (≈$1.32M).
• Phreesia reported Q1 EPS of $0.02 versus $0.07 expected while revenue rose 15.9% to $127.07M; the stock traded up 6.1% to $8.55 but remains near its 1-year low and well below the consensus price target of $20.82.
• Analysts have trimmed price targets and mixed ratings (consensus a Moderate Buy), while institutional investors increased positions—institutions now own about 92.1% of the company, with notable buys from RBC, AQR and Goldman Sachs.

Phreesia, Inc. (NYSE:PHR - Get Free Report) General Counsel Allison Hoffman sold 14,483 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $8.07, for a total value of $116,877.81. Following the transaction, the general counsel owned 163,485 shares of the company's stock, valued at approximately $1,319,323.95. This represents a 8.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phreesia Trading Up 6.1%

PHR traded up $0.49 during mid-day trading on Monday, hitting $8.55. 2,201,789 shares of the stock were exchanged, compared to its average volume of 2,867,051. The firm's fifty day moving average is $11.23 and its two-hundred day moving average is $16.60. Phreesia, Inc. has a 1-year low of $7.77 and a 1-year high of $32.76. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.41. The company has a market cap of $519.74 million, a PE ratio of 285.13 and a beta of 0.86.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. During the same period in the previous year, the company posted ($0.11) EPS. Phreesia's revenue was up 15.9% on a year-over-year basis. Equities analysts forecast that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of PHR. Royal Bank of Canada raised its stake in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company's stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC increased its position in Phreesia by 471.2% in the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company's stock valued at $4,090,000 after acquiring an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company's stock valued at $1,599,000 after acquiring an additional 2,158 shares during the period. NewEdge Advisors LLC increased its position in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company's stock valued at $395,000 after acquiring an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company's stock valued at $15,336,000 after acquiring an additional 2,402 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PHR. KeyCorp decreased their target price on Phreesia from $15.00 to $12.00 and set an "overweight" rating on the stock in a research note on Monday. Wall Street Zen lowered Phreesia from a "buy" rating to a "hold" rating in a research note on Saturday, April 4th. DA Davidson reduced their price target on Phreesia from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, January 23rd. JPMorgan Chase & Co. restated a "neutral" rating and set a $16.00 price objective (down from $24.00) on shares of Phreesia in a research note on Tuesday, March 31st. Finally, Stephens cut their price target on Phreesia from $32.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 31st. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $20.82.

About Phreesia

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.